{
    "title": "Novartis drug cuts recurrence risk by 25% in early-stage breast cancer",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12152327/Novartis-drug-cuts-recurrence-risk-25-early-stage-breast-cancer.html",
    "date": "2023-06-02",
    "keywords": [
        "cancer",
        "risk",
        "recurrence",
        "trial",
        "kisqali",
        "novartis",
        "market",
        "verzenio",
        "burger",
        "drug",
        "drugmaker",
        "status",
        "oncology",
        "therapy",
        "march",
        "growth",
        "surgery",
        "approval",
        "wider",
        "diarrhea",
        "stage",
        "eli",
        "company",
        "friday",
        "reduction",
        "regardless",
        "progression",
        "meeting",
        "society",
        "chicago",
        "endocrine",
        "type",
        "response",
        "preview",
        "breast",
        "body",
        "share",
        "ibrance",
        "diagnosis",
        "tumours",
        "half",
        "setting",
        "subset",
        "lymph",
        "competition",
        "group",
        "pioneer",
        "highrisk",
        "mediumrisk",
        "population",
        "readout",
        "side",
        "treatment",
        "lillys",
        "event",
        "jeff",
        "head",
        "hematology",
        "development",
        "update",
        "confidence",
        "vas",
        "narasimhan",
        "core",
        "income",
        "margin",
        "use",
        "end",
        "year",
        "reporting",
        "sriraj",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}